While known for weight loss, GLP-1 agonists are also highly effective for managing hyperglycemia from both steroids and PI3K inhibitors. Using low or "micro" doses can be very helpful in cancer patients, providing glucose control while minimizing GI side effects like nausea.

Long-term, high-dose GLP-1 use leads to diminishing returns and significant muscle loss. A more effective strategy is using micro-doses in 90-day cycles, paired with nutritional coaching. This approach uses the drug as a temporary tool to eliminate carb cravings and establish lasting dietary habits.

When stopping GLP-1 drugs like Ozempic, hunger doesn't just return to normal; it comes back with a "ferocious, animalistic" vengeance that is far more intense than before starting the medication. This powerful rebound effect is a primary driver of rapid weight regain.

Early retrospective data from major cancer centers suggests patients on hormone therapy experience less weight loss with GLP-1 agonists. This indicates a potential drug interaction that may require clinicians to more closely monitor weight trends and consider dose adjustments for this patient population.

Contrary to Wall Street's focus on ever-increasing efficacy, real-world data shows GLP-1 users optimize for tolerability. They prefer a sustainable dose that offers health benefits without severe side effects, maximizing their ability to stay on the drug long-term.

Beyond weight management, preliminary evidence suggests GLP-1 agonists may help with vasomotor symptoms (hot flashes) and arthralgia (joint pain). The proposed mechanism is indirect, likely through reduced inflammation from fat loss and less mechanical load on joints, representing a novel potential benefit for patients.

As the obesity market matures, the key differentiator may shift from maximum weight loss to tolerability. High discontinuation rates for GLP-1s due to GI side effects create an opportunity for drugs with slightly lower efficacy but a stellar safety profile, which could capture a large and underserved patient segment.

A major problem with GLP-1 drugs is that users often regain weight after stopping because they haven't learned new habits. Nutrisense addresses this by providing data and coaching to build sustainable lifestyle changes, making it a complementary, long-term solution.

The obesity market is evolving beyond maximum weight loss. Key differentiators will become dosing convenience, side effect profiles, and preserving lean muscle. This creates space for novel mechanisms, potentially as add-on therapies to lower GLP-1 doses and mitigate side effects.